Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with antiplatelet agent (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).
1 finding from 1 review
Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Exacerbation frequency · people with bronchiectasis
14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).
2 findings from 1 review
RR 0.75 [0.61, 0.93]
Studies not reported
Moderate
no estimate extracted
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Antibiotic resistance · people with bronchiectasis
28 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 28 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 2.2 [1.42, 3.42]
Studies not reported
High
Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.79 [0.49, 1.29]
Studies not reported
High
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
Moderate
no estimate extracted
Studies not reported
Low
Exacerbation frequency · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in exacerbation frequency compared with 28 days on/off antibiotic regimen (moderate certainty).
2 findings from 1 review
RR 1.02 [0.84, 1.24]
Studies not reported
Moderate
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Antibiotic resistance · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in antibiotic resistance compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 1 [0.68, 1.48]
Studies not reported
Moderate
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
High
no estimate extracted
Studies not reported
High